Last reviewed · How we verify
MK-2214
At a glance
| Generic name | MK-2214 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) (PHASE2)
- A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-2214 CI brief — competitive landscape report
- MK-2214 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI